{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Biliary+Tract+Cancer", "query": { "condition": "Metastatic Biliary Tract Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 149, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Biliary+Tract+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T21:46:28.456Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04426669", "title": "A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Epithelial Cancer", "Gastrointestinal Neoplasms", "Cancer of Gastrointestinal Tract", "Cancer, Gastrointestinal", "Gastrointestinal Cancer", "Colo-rectal Cancer", "Pancreatic Cancer", "Gall Bladder Cancer", "Colon Cancer", "Esophageal Cancer", "Stomach Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tumor-Infiltrating Lymphocytes (TIL)", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intima Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 23, "start_date": "2020-05-15", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04426669" }, { "nct_id": "NCT00021047", "title": "Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "epirubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Portsmouth, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portsmouth", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021047" }, { "nct_id": "NCT03337087", "title": "Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Biliary Tract Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Sucrosofate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-11-02", "completion_date": "2025-08-09", "has_results": true, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03337087" }, { "nct_id": "NCT00003439", "title": "Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "recombinant interleukin-12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "1998-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003439" }, { "nct_id": "NCT07197554", "title": "A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ewing Sarcoma", "Hepatocellular Carcinoma (HCC)", "Biliary Tract Cancer (BTC)" ], "interventions": [ { "name": "ST-01156", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SEED Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 171, "start_date": "2025-12-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 6, "location_summary": "Duarte, California • Newport Beach, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07197554" }, { "nct_id": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Advanced Solid Tumor" ], "interventions": [ { "name": "DB-1303/BNT323", "type": "BIOLOGICAL" }, { "name": "Pertuzumab Injection", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "DualityBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 796, "start_date": "2022-01-31", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 35, "location_summary": "Cerritos, California • Los Angeles, California • San Diego, California + 29 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150691" }, { "nct_id": "NCT05489211", "title": "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Gastric Cancer", "Metastatic Castration-resistant Prostate Cancer", "Ovarian Cancer", "Colorectal Cancer", "Urothelial Cancer", "Biliary Tract Cancer" ], "interventions": [ { "name": "Datopotamab deruxtecan (Dato-DXd)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Volrustomig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Prednisone/ prednisolone", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 454, "start_date": "2022-09-06", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 18, "location_summary": "Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Muncie", "state": "Indiana" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05489211" }, { "nct_id": "NCT03639935", "title": "Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Biliary Tract Cancer" ], "interventions": [ { "name": "Rucaparib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-28", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03639935" }, { "nct_id": "NCT07107750", "title": "Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Biliary Tract Cancer", "Metastatic Biliary Tract Carcinoma" ], "interventions": [ { "name": "Emavusertib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2026-03-27", "completion_date": "2032-05-31", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07107750" }, { "nct_id": "NCT02856568", "title": "Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Resectable Cholangiocarcinoma", "Recurrent Cholangiocarcinoma", "Stage III Extrahepatic Bile Duct Cancer", "Stage III Intrahepatic Cholangiocarcinoma", "Stage IIIA Hilar Cholangiocarcinoma", "Stage IIIB Hilar Cholangiocarcinoma", "Stage IVA Extrahepatic Bile Duct Cancer", "Stage IVA Hilar Cholangiocarcinoma", "Stage IVA Intrahepatic Cholangiocarcinoma", "Stage IVB Extrahepatic Bile Duct Cancer", "Stage IVB Hilar Cholangiocarcinoma", "Stage IVB Intrahepatic Cholangiocarcinoma", "Unresectable Extrahepatic Bile Duct Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ricolinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-05-01", "completion_date": "2021-10", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-06-07T21:46:28.456Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02856568" } ] }